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Background: In animal models, lack of thyroid hormone is associated with cone photoreceptor preservation, while
administration of high doses of active thyroid hormone leads to deterioration. The association between thyroid
function and age-related macular degeneration (AMD) has not been investigated in the general population.
Methods: Participants of age ≥55 years from the Rotterdam Study with thyroid-stimulating hormone (TSH) and/or
free thyroxine (FT4) measurements and AMD assessment were included. We conducted age- and sex-adjusted Cox
proportional hazards models to explore the association of TSH or FT4 with AMD, in the full range and in those with
TSH (0.4-4.0 mIU/L) and/or FT4 in normal range (11–25 pmol/L). Cox proportional hazards models were performed
for the association of TSH or FT4 with retinal pigment alterations (RPA), as an early marker of retinal changes.
Multivariable models additionally included cardiovascular risk factors and thyroid peroxidase antibodies positivity.
We also performed stratification by age and sex. A bidirectional look-up in genome-wide association study (GWAS)
data for thyroid parameters and AMD was performed. Single nucleotide polymorphisms (SNPs) that are significantly
associated with both phenotypes were identified.
Results: We included 5,573 participants with a median follow-up of 6.9 years (interquartile range 4.4-10.8 years).
During follow-up 805 people developed AMD. TSH levels were not associated with increased risk of AMD. Within
normal range of FT4, participants in the highest FT4 quintile had a 1.34-fold increased risk of developing AMD,
compared to individuals in the middle group (95% confidence interval [CI] 1.07-1.66). Higher FT4 values in the full
range were associated with a higher risk of AMD (hazard ratio 1.04, CI, 1.01-1.06 per 1 pmol/L increase). Higher FT4
levels were similarly associated with a higher risk of RPA. Restricting analyses to euthyroid individuals, additional
multivariable models, and stratification did not change estimates. We found a SNP (rs943080) in the VEGF-A gene,
associated with AMD, to be significant in the TSH GWAS (P = 1.2 x 10−4). Adding this SNP to multivariable models
did not change estimates.
Conclusions: Higher FT4 values are associated with increased risk of AMD - even in euthyroid individuals - and
increased risk of RPA. Our data suggest an important role of thyroid hormone in pathways leading to AMD.
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Age-related macular degeneration (AMD) is a disease of
the retina in the elderly which can lead to irreversible
blindness and is characterized by drusen, pigmentary
changes, choroidal neovascularization, and geographic
atrophy. While AMD is one of the leading causes of vis-
ual impairment worldwide and increasing in prevalence
[1-7], the exact pathophysiology and pathways leading to
AMD are not entirely understood. Thyroid hormones
are known to regulate various visual functions in experi-
mental and human studies [8-10]. Human retinal pig-
ment epithelial (RPE) cells express thyroid hormone
receptors and seem to be a direct target for thyroid hor-
mones [11]. Recently it was shown that suppression of
thyroid hormone signaling resulted in preservation of
cone photoreceptors in mouse models of retinal degen-
eration [12]. In contrast, administration of active thyroid
hormone leads to deterioration of cones. Thyroid dys-
function and subclinical thyroid dysfunction are com-
mon in the general population, with a prevalence up to
10% [13-16]. These thyroid disorders are associated with
various cardiovascular risk factors, including alterations
in lipid levels, atherosclerosis, and hypertension [17-19],
which are known predisposing factors for development
and progression of AMD [20,21]. However, there are
no studies in the general population assessing the associ-
ation between thyroid function and the risk of AMD.
Therefore, we aimed to assess the relation between
thyroid-stimulating hormone (TSH), free thyroxine (FT4),
and the risk of incident AMD in a prospective population-
based cohort study and to study possible underlying gen-
etic pathways by investigating an overlap in genome-wide
significant hits (that is, bidirectional genetic look-up).
Methods
The Rotterdam Study
The Rotterdam Study is a prospective population-based
cohort study that addresses determinants and occurrence
of cardiovascular, neurological, ophthalmologic, psychi-
atric, and endocrine diseases in the elderly living in
Ommoord, a suburb of Rotterdam. The aims and design of
the Rotterdam study have been described in detail else-
where [22]. For this analysis we included participants from
two independent cohorts from the Rotterdam Study. The
Rotterdam Study Cohort 1 (RSI) started in 1989 and in-
cluded a total of 7,983 participants (response rate 78%)
aged 55 years and older. Baseline data were collected from
1990 until 1993, and four follow-up examinations were
performed in 1993–1995, 1997–1999, 2002–2004, and
2009–2011. The second cohort is the Rotterdam Study
Cohort II (RSII), which includes a total of 3,011 partici-
pants (response rate 67%) aged 55 years and older. Baseline
data were collected from 2000–2001, and follow-up exami-
nations were performed in 2004–2005 and 2011–2012.Study population
Participants from baseline study cohorts RSI (RSI-1) and
RSII (RSII-1) were eligible for these analyses if they had
TSH and/or FT4 measurements and had gradable fun-
dus photographs at baseline and at least one follow-up
eye examination. Since not all participants from RSI had
thyroid measurements at baseline, additional baseline
samples were drawn from RSI visit 3 (RSI-3). Participants
with AMD at baseline (N = 567) were excluded from
further analyses. In total, 5,573 participants from these
two cohorts were eligible to be included in our analyses
(Additional file 1: Figure S1). The Medical Ethics Commit-
tee of the Erasmus University approved the study proto-
cols, and participants gave a written informed consent in
accordance with the Declaration of Helsinki.
Assessment of thyroid function
For RSI-1, serum TSH (TSH Lumitest; Henning, Berlin,
Germany), anti-TPOAb (ELISA; Milenia; Diagnostic Products
Corp, Los Angeles, CA, USA) and free T4 levels (FT4;
Vitros, ECI Immunodiagnostic System; Ortho-Clinical
Diagnostics, Amersham, UK) were determined in a ran-
dom subset of the baseline serum samples (n = 1,855).
Thyroid function assessment was also performed in base-
line serum samples for TSH and FT4 (electrochemilumi-
nescence immunoassay for thyroxine and thyrotropine,
“ECLIA”, Roche) for RSI-3 and RSII-1. The tests’ TSH ref-
erence ranges did not differ substantially and had a good
Spearman correlation coefficient (0.96 for TSH, P < 0.0001
and 0.81 for FT4, P < 0.0001). We determined the cut-off
values for normal range TSH as 0.4-4.0 mIU/L according
to national guidelines. The reference range for FT4 was
11–25 pmol/L, and anti-TPOAb levels greater than 60
kU/mL were regarded as positive.
Diagnosis of age-related macular degeneration
All eligible participants underwent fundus photography
after pharmacologic mydriasis. For visits RSI-1 to RSI-3
and RSII-1 a 35° film fundus camera was used (Topcon
TRV-50VT, Topcon Optical Company, Tokyo, Japan),
after which a 35° digital color fundus camera (Topcon
TRC-50EX, Topcon Optical Company, Tokyo, Japan
with a Sony DXC-950P digital camera; 0.44 megapixel,
Sony Corporation, Tokyo, Japan) followed for visits RSI-4,
RSI-5, RSII-2, and RSII-3. Fundus transparencies were
graded according to the Wisconsin age-related maculopa-
thy grading system [23] and the modified International
Classification System [24] by trained graders under the
supervision of senior retinal specialists (JRV, CCWK). The
eyes of each participant were graded and classified separ-
ately, and the eye with the more severe grade was used to
classify the person. In the analyses incident early and late
AMD combined was used as the outcome variable. In the
manuscript this is referred to as AMD. Besides AMD we
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come variable. These lesions included retinal pigmentary
alterations, large drusen (≥125 μm), and large drusen area
(≥5,331,820 μm2) [25].
Baseline measurements
Smoking was derived from computerized baseline ques-
tionnaires, and participants were categorized as current
or non-current smokers. Blood pressure, systolic and
diastolic, was calculated as the average of two consecu-
tive measurements, using random-zero mercury sphyg-
momanometers. Hypertension was defined as a systolic
blood pressure ≥ 140 mmHg or a diastolic blood pres-
sure ≥ 90 mmHg or participant use of anti-hypertensive
medication at baseline. Cholesterol was measured at base-
line by the CKCL (Centra Clinical Chemical Laboratory)
of the Erasmus University Medical Center. A subgroup of
measurements was carried out in the laboratory of the
Department of Epidemiology and Biostatistics (Erasmus
University Medical School). History of diabetes was de-
fined by a repeated impaired fasting glucose ≥ 7 or use
of anti-glycemic medication at baseline. Body mass
index (BMI) was calculated as weight in kilograms di-
vided by height in meters squared.
Statistical analysis
Participant baseline characteristics were compared using
a χ2 or t-test. Due to a skewed distribution, TSH was
log-transformed for the statistical analyses. We used the
Cox proportional hazards model to calculate the rela-
tionship between TSH and FT4 at baseline and the risk
of incident AMD, first including all participants and
then including only those with normal range TSH and/
or FT4 values. We performed a crude Cox model includ-
ing only thyroid parameters, after which we also in-
cluded quadratic and cubic terms to explore possible
nonlinear relationships. We then performed additional
models adjusting first for age and sex and second also
adding smoking, hypertension, cholesterol, diabetes, and
BMI to the model. Hypertension, cholesterol, diabetes,
and BMI could act as confounders and possible media-
tors depending on the presumed pathway through which
thyroid function is related to AMD. These variables were
included in the multivariable model as possible con-
founders of non-vascular pathways. We looked at the
association between AMD and TSH or FT4 both con-
tinuously and in quintiles, as well as overall and within
the normal range of TSH. The middle quintile was used
as a reference group, as biologically it is expected to
represent the subgroup with the most normal thyroid
function within the euthyroid group. We performed pre-
defined stratification by sex and age categories, using a
cutoff of 65 years, as this is the median of the current
population and the treatment threshold for subclinicalthyroid dysfunction according to the European guide-
lines [26]. Further interaction terms were introduced to
the model to explore possible differential risk patterns.
We performed a sensitivity analysis excluding those
using thyroid medication at baseline (levothyroxine and
anti-thyroid drugs) and those with prior self-reported
thyroid disease at baseline. We also performed FT4 and
TSH analyses with specific AMD lesions defined as ret-
inal pigment alteration, large drusen, and large drusen
area as separate outcome variables to examine possible
early changes in underlying pathways. To address the
issue of drop-out of individuals during follow-up that
could possibly not be completely at random, we adjusted
the model for inverse probability weights (IPWs). These
were calculated using possible baseline explanatory vari-
ables for drop-out such as smoking, BMI, and medica-
tion use. The proportional hazards assumption was
checked statistically using the Schoenfeld test and asses-
sing the Schoenfeld plot. All statistical analyses were
performed using SPSS version 21 (IBM SPSS, Armonk,
NY, USA) except for the Schoenfeld tests and (Schoen-
feld) plots which were performed in R (survival package,
R-project, Institute for Statistics and Mathematics, R
Core Team (2013), Vienna, Austria, version 3.0.2).
Bidirectional genetic look-up
Genome-wide association studies (GWASs) have been per-
formed for AMD [27] and thyroid function (TSH and
FT4) [28,29]. These studies identified several single nucleo-
tide polymorphisms (SNPs) associated to these two pheno-
types. Some of the genome-wide significant SNPs in the
AMD GWAS might also play a role in thyroid function
and vice versa. Overlap between common genetic polymor-
phisms can provide insight into possible shared genetic
pathways. It might also elucidate a mediation effect be-
tween the two phenotypes, that is, identify and explicate
the process that underlies a possible observed relationship
between thyroid function and AMD. To evaluate these po-
tential genetic pathways, we conducted a bidirectional gen-
etic look-up using the results of the above mentioned
GWASs for AMD and thyroid function. We first extracted
SNPs that reached genome-wide significance from the
AMD GWAS performed by the AMD Gene Consortium
[27]. We then checked whether these were significantly as-
sociated with TSH or FT4 in the thyroid function GWAS
performed by Porcu et al. [28]. Hereafter we extracted
the genome-wide significant SNPs for TSH or FT4 from
the thyroid function GWAS and checked whether they
were associated with AMD in the AMD GWAS. For the
significance level, we applied a multiple testing correction
(Bonferroni correction), using a P-value threshold of 0.05
divided by the amount of significant SNPs per GWAS. In
case of a significant finding, we added the SNP to the mul-
tivariable model to evaluate a possible mediation effect.
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We included 5,573 participants with TSH and/or FT4
measurements at baseline and incident AMD data, with a
median follow-up of 6.9 years (interquartile range [IQR]
of 4.4-10.8 years). Of these, 5,572 had TSH and 5,504 had
FT4 baseline measurements. A total of 805 people devel-
oped AMD (early AMD N= 725, late AMD N= 80) dur-
ing follow-up with an incidence rate of 18 per 1,000
person-years. The baseline characteristics for those with
and without incident AMD during follow-up were com-
parable, except for the proportion of diabetes (Table 1).
Association between thyroid function and AMD
Although there was no association between TSH and
AMD (hazard ratio [HR] 0.99; 95% confidence interval
[CI] 0.91-1.07, Table 2), the risk of AMD was signifi-
cantly increased in those with higher FT4 levels (Table 2).
When categorizing the FT4 values within normal range
in quintiles, those in the highest FT4 quintile had an in-
creased risk compared to the middle group with an HR
of 1.34 (95% CI, 1.07-1.66) and a non-significant P for
interaction (P = 0.066) (Table 2). This association remained
similar after additional adjustments for smoking, diabetes,
hypertension, cholesterol, BMI, and TPOAb positivity
(Figure 1). This association also remained similar after
analyzing only those within the normal range of TSH and
FT4, that is, those with normal thyroid function. Exclud-
ing those with thyroid medication or thyroid disease at
baseline as a sensitivity analysis did not alter the associ-
ation (Table 3). Stratifying for age and sex did not revealTable 1 Baseline characteristics of included participants
from the Rotterdam Study evaluating the association
between thyroid function and AMD*
Variable No incident
AMD
Incident
AMD
N = 4,768 N = 805 P-value**
Age, years 67.6 (7.6) 67.9 (7.1) 0.29
Sex, % female 57.6 57.8 0.94
History of diabetes, % 10.8 8.4 0.04
BMI, kg/m2 26.9 (3.9) 26.6 (3.7) 0.07
Cholesterol, mmol/L 6.1 (1.2) 6.1 (1.1) 0.23
Smoking, % current 20.7 21.0 0.85
Hypertension, % 63.0 58.7 0.17
TSH, mIU/L median (IQR) 1.78 (1.15-2.69) 1.73 (1.17-2.67) 0.78
FT4, pmol/L 15.8 (2.6) 16.0 (3.2) 0.13
TPOAb, kU/L 30.5 (95.1) 30.8 (96.2) 0.93
*Values are means and SD unless otherwise specified.
**For comparison a t-test was conducted, for TSH the log-transformed values
were used.
Abbreviations: AMD age-related macular degeneration BMI body mass index,
TSH thyroid-stimulating hormone, FT4 = free thyroxine, SD standard deviation,
IQR interquartile range, TPOAb thyroid peroxidase antibodies.any significant differential risk (Additional file 1: Table S1).
The association between thyroid function and retinal pig-
ment alterations for FT4 showed similar significant HRs,
with the exception of the risk estimates when looking at
FT4 only in the normal range of TSH (Table 4). TSH and
FT4 were not associated with large drusen or large drusen
area (data not shown). Introducing quadratic and cubic
terms for TSH and FT4 to the crude model, as an explor-
ation of non-linearity, did not improve model perform-
ance. Taking possible non-random follow-up using IPWs
did not change risk estimates. The proportional hazards
assumption was checked statistically with the Schoenfeld
test and Schoenfeld plot and met for both the TSH
(P = 0.232) and FT4 (P = 0.154) analyses.
Bidirectional genetic look-up
In the thyroid function GWAS, 20 SNPs were associated
with TSH and 6 with FT4 [28]. The AMD GWAS re-
vealed 19 genome-wide significant SNPs related to the
phenotype. None of the SNPs from the thyroid function
GWAS were significant in the AMD GWAS. One SNP
(rs943080) in the vascular endothelial growth factor A
(VEGF-A) gene that is related to AMD was also signifi-
cantly associated with TSH (P = 1.2 × 10−4, significance
threshold =0.0026) (Additional file 1: Table S2). Within
our study population, GWAS data were available for a
total 4,646 participants. Additionally correcting for
the rs943080 SNP in the most adjusted model in these
participants resulted in similar risk estimates for the
FT4 analysis (HR 1.04, CI 95% 1.01-1.07). Stratifying
for this SNP did show risk differences between the dif-
ferent genotypes but not significantly (Additional file 1:
Table S1).
Discussion
In this prospective cohort study we investigated the as-
sociation between thyroid function and incidence of
AMD. Higher FT4 values were associated with an in-
creased risk of developing AMD, even within the normal
range of TSH and FT4 (that is, euthyroid subjects), while
there was no association between TSH and AMD. The
similar findings between higher FT4 levels and retinal
pigment alterations might suggest that thyroid hormone
plays a role in the development of AMD rather than just
acting as a promoter of disease. To our knowledge, this
is the first prospective population-based cohort study
to look at the association between thyroid function
and AMD.
A limited number of studies investigating thyroid dis-
ease and AMD have been published, all lacking labora-
tory assessment of thyroid function. Bromfield et al.
reported an increased risk of AMD in subjects with self-
reported hypothyroidism [30]. A case–control study by
Anand et al. reported an association between thyroid
Table 2 Association between TSH, FT4, and risk of AMD
Incident AMD versus no AMD AMD N Total N HR (95% CI), model 1 HR (95% CI), model 2 HR (95% CI), model 3
TSH, mIU/L 805 5,572 0.99 (0.91-1.07) 0.99 (0.91-1.07) 0.99 (0.91-1.07)
TSH in normal rangea 696 4,756 1.06 (0.91-1.23) 1.09 (0.93-1.27) 1.08 (0.93-1.26)
Normal range TSHa
Q1 0.40-1.10 148 1,082 1.04 (0.82-1.32) 1.00 (0.79-1.28) 1.00 (0.79-1.28)
Q2 1.11-1.54 167 990 1.32 (1.04-1.66) 1.29 (1.02-1.62) 1.29 (1.02-1.62)
Q3 1.55-1.99 128 962 reference reference reference
Q4 2.00-2.61 117 851 1.09 (0.85-1.40) 1.07 (0.83-1.37) 1.07 (0.83-1.38)
Q5 2.62-3.97 136 871 1.22 (0.96-1.56) 1.22 (0.95-1.55) 1.21 (0.94-1.54)
P interaction 0.648 0.485 0.517
Total 696 4,756
FT4, pmol/L 791 5,504 1.04 (1.01-1.06) 1.04 (1.01-1.06) 1.04 (1.01-1.06)
FT4 in normal rangeb 765 5,382 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
Normal range FT4b
Q1 11.0-14.0 149 1,090 1.03 (0.82-1.29) 1.04 (0.82-1.31) 1.04 (0.82-1.31)
Q2 14.0-15.1 152 1,001 1.12 (0.89-1.41) 1.17 (0.92-1.47) 1.16 (0.92-1.47)
Q3 15.1-16.2 144 1,094 reference reference reference
Q4 16.2-17.5 134 1,060 1.01 (0.80-1.28) 1.03 (0.81-1.30) 1.03 (0.81-1.31)
Q5 17.5-24.9 186 1,137 1.34 (1.07-1.66) 1.35 (1.08-1.69) 1.35 (1.09-1.69)
P interaction 765 5,382 0.066 0.088 0.080
Normal range FT4b in normal range TSHa 673 4,658 1.04 (1.01-1.08) 1.04 (1.01-1.08) 1.04 (1.01-1.07)
aNormal range of TSH defined as 0.4-4.0 mIU/L. bNormal range of FT4 defined as 11–25 pmol/L.
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI. Model 3: Model 2 + thyroid peroxidase
antibodies positivity.
Abbreviations: AMD age-related macular degeneration, BMI body mass index, CI confidence interval, FT4 free T4, HR hazard ratio, Q quintile, TSH thyroid-stimulating hormone.
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atrophy [31], but no data were reported on the number
of patients that were over- or undertreated. Similarly,
the Beaver Dam Eye study also reported an association
between thyroid hormone use and early AMD [32], but
this was not confirmed by Douglas et al. [33]. As men-
tioned previously, none of these studies had laboratoryFT4 pmol/L quintiles AMD N Total N
11.0 - 14.0 149 1090 1.
14.0 - 15.1 152 1001 1.
15.1 - 16.2 144 1094 [R
16.2 - 17.5 134 1060 1.
17.5 - 24.9 186 1137 1.
Figure 1 Quintiles of FT4 within the normal range and risk of AMD. The no
= 0.0777 ng/dL). aAnalyses were adjusted for sex, age, smoking, hypertensio
antibodies positivity. Abbreviations: AMD, age-related macular degenerationassessment of thyroid function nor did they investigate
the association in a time-to-event analysis. In our study,
excluding all subjects using thyroid medication did not
alter risk estimates, supporting a potential intrinsic effect
of thyroid hormone.
There are several pathophysiological explanations for
the relationship between thyroid hormones and AMD.HR Ratio
(95% CI)a
04 (0.82-1.31)
16 (0.92-1.47)
EFERENCE]
03 (0.81-1.31)
35 (1.09-1.69)
Decreased risk          Increased risk
0.50 1.00 2.50
Hazard Ratio (95% CI)
rmal range of FT4 was defined as 11–25 pmol/L (conversion 1 pmol/L
n, cholesterol, diabetes, body mass index, and thyroid peroxidase
; FT4, free thyroxine; HR, hazard ratio.
Table 3 Sensitivity analyses excluding participants with thyroid medication or thyroid disease at baseline
Incident AMD versus no AMD AMD N Total N HR (95% CI), model 1 HR (95% CI), model 2 HR (95% CI), model 3
Excluded thyroid medication
Free T4 752 5,225 1.03 (1.01-1.06) 1.03 (1.01-1.06) 1.03 (1.01-1.06)
TSH, mIU/L 778 5,417 0.99 (0.91-1.08) 1.00 (0.92-1.09) 1.00 (0.91-1.09)
Excluding baseline thyroid diseaseb
Free T4 751 5,237 1.04 (1.01-1.08) 1.04 (1.01-1.07) 1.04 (1.01-1.08)
TSH, mIU/L 764 5,300 0.98 (0.89-1.07) 0.98 (0.89-1.07) 0.97 (0.89-1.07)
a155 participants had thyroid medication (thyroid hormone use) at baseline.
b272 participants had self-reported thyroid disease at baseline.
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cholesterol, diabetes, BMI. Model 3: Model 2 + thyroid peroxidase
antibodies positivity.
Abbreviations: BMI body mass index, CI confidence interval, FT4 free thyroxine, HR hazard ratio, TSH thyroid-stimulating hormone.
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of thyroid hormone signaling resulted in preservation of
cone photoreceptors [12]. The same study found that
stimulating thyroid hormone signaling, by administering
the active thyroid hormone triiodothyronine, deteriorates
cones in mouse models with a slow progressive and mod-
erate degeneration phenotype [12]. In addition, mice lack-
ing type 3 deiodinase, the enzyme responsible for the
degradation of thyroid hormones, have decreased survival
and disturbed maturation of cone photoreceptors [34].
The findings of these studies suggest that thyroid hor-
mone may lead to a higher turnover of photoreceptors,
and in retinal degeneration this leads to deterioration of
photoreceptors. Beside photoreceptors, thyroid hormone
might also have an influence on the retinal pigment
epithelial cells [11]. In the healthy retina the turnover of
photoreceptors is extremely high. Every day the photore-
ceptors shed the ends of their outer segments, resulting in
full renewal every 10 days. These shedded parts of the
outer segments are phagocytosed by the retinal pigment
epithelium (RPE) cells [35]. Increase of the turnover of the
photoreceptors by thyroid hormone may bring additional
stress to the process. RPE cells at distress may change,
resulting in pigmentary alterations in the macular area.
The RPE cells may also be targeted directly by the thyroidTable 4 Association between FT4 and TSH with retinal pigme
Incident pigment alterations versus no pigment alterations Cases N
TSH, mIU/L 729
Normal range TSHb 618
FT4, pmol/L 720
Normal range FT4c 697
Normal range FT4c in normal range TSHb 601
aParticipants with late AMD were excluded from this analysis.
bNormal range of TSH defined as 0.4-4.0 mIU/L.
cNormal range of FT4 defined as 11–25 pmol/L.
Model 1: Adjusted for sex and age. Model 2: Model 1 + smoking, hypertension, cho
antibodies positivity.
Abbreviations: BMI body mass index, CI confidence interval, FT4 free thyroxine, HR hhormone, resulting in these changes [11]. These results
may provide an explanation for the findings in our study.
Thyroid dysfunction has been linked to cardiovascular
risk factors and disease, including effects on the vascular
function, lipids, and atherosclerosis [36]. As some of
these risk factors are also linked to AMD [20,21], one
could speculate about a joint vascular pathway leading
to both thyroid dysfunction and AMD or perhaps that
the relation between thyroid dysfunction and AMD
could be mediated through this pathway. We were not
able to confirm these hypotheses. First of all, these car-
diovascular risk factors are mainly seen in hypothyroidism,
(high TSH and low FT4), whereas our data show an asso-
ciation between high FT4 and AMD. Also, correcting
for some of these risk factors (for example, hypertension)
that could act as confounders and possible mediators did
not change risk estimates, suggesting that the effect of thy-
roid function is not through these pathways. Lastly, the
VEGF-A gene was found to be significant in the look-up
for the TSH GWAS and not the FT4 GWAS. However,
our results suggest a higher risk of AMD in higher levels
of FT4 and not in TSH. Furthermore, the association did
not change by adding this SNP to the multivariable model.
We find an effect with FT4 but not with TSH, which
seems to be in line with previous literature from cohortnt alterationsa
Total N HR (95% CI),
model 1
HR (95% CI),
model 2
HR (95% CI),
model 3
5,401 0.98 (0.90-1.06) 0.97 (0.90-1.06) 0.96 (0.88-1.04)
4,591 1.02 (0.87-1.20) 1.05 (0.89-1.23) 1.04 (0.88-1.22)
5,338 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
5,226 1.04 (1.01-1.07) 1.04 (1.01-1.07) 1.04 (1.01-1.07)
4,500 1.03 (1.00-1.07) 1.03 (0.99-1.06) 1.03 (0.99-1.06)
lesterol, diabetes, BMI. Model 3: Model 2 + thyroid peroxidase
azard ratio, TSH thyroid-stimulating hormone.
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between thyroid function and several other endpoints
[37,38]. Regulation of serum thyroid hormone levels is
controlled by the hypothalamus-pituitary-thyroid axis.
The set point of this feedback mechanism is defined in-
dividually, with thyroid hormone levels showing a much
greater inter-individual than intra-individual variability
[39]. The individual set point can be modulated by sev-
eral pathophysiological (for example, critical illness) and
physiological (for example, ageing) mechanisms [40].
This could explain why in this elderly and ageing popu-
lation we do find an association with FT4 but not with
TSH, especially in the euthyroid range. Furthermore, pre-
vious literature results showed an increase in TSH with
increasing age, suggesting that higher TSH levels are
needed to keep thyroid hormone levels within the desired
range [38]. We only have thyroid function measures at
baseline and are therefore not able to investigate whether
changes in thyroid function over time explain the discord-
ant association between TSH, FT4, and AMD.
Important strengths of our study are the assessment of
thyroid function at baseline through laboratory testing as
well as the elaborate assessment of AMD at baseline and
follow-up. Also, we were able to investigate the association
between thyroid function and specific AMD lesions like ret-
inal pigment alterations to examine possible early changes
in underlying pathways. The availability of genetic data gave
us the opportunity to explore possible genetic pathways.
The bidirectional genetic look-up, revealed one SNP in the
VEGF-A gene to be significant in the TSH GWAS, but not
for FT4. Adding this SNP to the multivariate model did not
alter risk estimates. An explanation for the absence of over-
lapping genome-wide significant SNPs could be that these
GWASs were underpowered for this association.
A limitation of our study is that thyroid parameters were
measured once at baseline. Therefore, the evolution of
thyroid hormone levels could not be taken into account.
Also, residual confounding cannot be excluded, even with
the large number of covariates included in these analyses.
Lastly, this study is conducted in a mainly Caucasian popu-
lation of 55 years and older and may not be generalizable
to other populations.
Conclusions
We find an increased risk of incident AMD in subjects
with higher FT4 levels, even in those with a normal thy-
roid function and when excluding thyroid medication
users. This implies an intrinsic (that is, not exogenous)
deleterious effect of thyroid hormone on AMD. We also
find an association between higher FT4 levels and retinal
pigment alterations, suggesting that thyroid hormone
could even play a role in the early stage of development
of AMD. Functional and clinical studies could provide
more evidence for a true causal relationship.Additional file
Additional file 1: Figure S1. Flow chart for inclusion of participants
from the Rotterdam Study. Abbreviations: AMD, age-related macular
degeneration; RS, Rotterdam Study. Table S1a. Stratification analysis
of the association between TSH in normal range and risk of AMD.
Table S1b. Stratification analysis of the association between FT4 in
normal range TSH and risk of AMD. Table S2a. Associations of
genome-wide significant AMD hits with TSH and FT4 levels; look-up in
TSH-FT4 GWAS. Table S2b. Association of genome-wide significant TSH
and FT4 SNPS with late AMD; look-up in AMD GWAS.Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LC and GHSB designed and performed the study, analyzed the data,
conducted the statistical analyses, evaluated the results, and wrote and
edited the manuscript. CCWK and RPP conceived and participated in the
study design. AD, MM, AH, JRV, OHF, CCWK, and RPP evaluated the results,
contributed to the discussion, and edited the manuscript. All authors read
and approved the final manuscript.
Acknowledgments
We are grateful to the study participants, the staff from the Rotterdam Study,
and the participating general practitioners and pharmacists.
Dr. A. Dehghan is supported by an NWO grant (veni, 916.12.154) and the
EUR Fellowship. Prof. O. H. Franco works in ErasmusAGE, a center for aging
research across the life course funded by Nestle’ Nutrition (Nestec Ltd.),
Metagenics Inc., and AXA. Nestle’ Nutrition (Nestec Ltd.), Metagenics Inc., and
AXA had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review and approval of the manuscript. Dr. R.P. Peeters is supported by a
Zon-MWTOP grant (number 91212044) and an Erasmus MC MRACE grant.
Author details
1Rotterdam Thyroid Center, Erasmus University Medical Center, Rotterdam,
The Netherlands. 2Department of Internal Medicine, Erasmus University
Medical Center, Rotterdam, The Netherlands. 3Department of Epidemiology,
Erasmus University Medical Center, Rotterdam, The Netherlands.
4Department of Ophthalmology, Erasmus University Medical Center,
Rotterdam, The Netherlands. 5Department of Internal Medicine, Rotterdam
Thyroid Center, Erasmus University Medical Center, Endocrinology, Erasmus
University Medical Center Rotterdam, Room Ee502, PO Box 2040, 3000, CA,
Rotterdam, The Netherlands.
Received: 14 January 2015 Accepted: 17 March 2015
References
1. Bourne RRA, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al.
Prevalence and causes of vision loss in high-income countries and in
Eastern and Central Europe: 1990–2010. British J Ophthalmol. 2014;98:629–38.
2. Jonas JB, George R, Asokan R, Flaxman SR, Keeffe J, Leasher J, et al.
Prevalence and causes of vision loss in Central and South Asia: 1990–2010.
British J Ophthalmol. 2014;98:592–8.
3. Keeffe J, Taylor HR, Fotis K, Pesudovs K, Flaxman SR, Jonas JB, et al.
Prevalence and causes of vision loss in Southeast Asia and Oceania:
1990–2010. British J Ophthalmol. 2014;98:586–91.
4. Khairallah M, Kahloun R, Flaxman SR, Jonas JB, Keeffe J, Leasher J, et al.
Prevalence and causes of vision loss in North Africa and the Middle East:
1990–2010. British J Ophthalmol. 2014;98:605–11.
5. Leasher JL, Lansingh V, Flaxman SR, Jonas JB, Keeffe J, Naidoo K, et al.
Prevalence and causes of vision loss in Latin America and the Caribbean:
1990–2010. British J Ophthalmol. 2014;98:619–28.
6. Naidoo K, Gichuhi S, Basanez MG, Flaxman SR, Jonas JB, Keeffe J, et al.
Prevalence and causes of vision loss in sub-Saharan Africa: 1990–2010.
British J Ophthalmol. 2014;98:612–8.
Chaker et al. BMC Medicine  (2015) 13:94 Page 8 of 87. Wong TY, Zheng YF, Jonas JB, Flaxman SR, Keeffe J, Leasher J, et al.
Prevalence and causes of vision loss in East Asia: 1990–2010. British J
Ophthalmol. 2014;98:599–604.
8. Ittermann T, Dorr M, Volzke H, Tost F, Lehmphul I, Kohrle J, et al. High
serum thyrotropin levels are associated with retinal arteriolar narrowing in
the general population. Thyroid. 2014;24:1473–8.
9. Takeda M, Kakegawa T, Suzuki M. Effect of thyroidectomy on photoreceptor
cells in adult rat retina. Life Sci. 1996;58:631–7.
10. Takeda M, Onoda N, Suzuki M. Characterization of thyroid hormone effect
on the visual system of the adult rat. Thyroid. 1994;4:467–74.
11. Duncan KG, Bailey KR, Baxter JD, Schwartz DM. The human fetal retinal
pigment epithelium: a target tissue for thyroid hormones. Ophthalmic Res.
1999;31:399–406.
12. Ma H, Thapa A, Morris L, Redmond TM, Baehr W, Ding XQ. Suppressing
thyroid hormone signaling preserves cone photoreceptors in mouse
models of retinal degeneration. Proc Natl Acad Sci U S A. 2014;111:3602–7.
13. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid
disease prevalence study. Arch Intern Med. 2000;160:526–34.
14. Aghini-Lombardi F, Antonangeli L, Martino E, Vitti P, Maccherini D, Leoli F,
et al. The spectrum of thyroid disorders in an iodine-deficient community:
the Pescopagano survey. J Clin Endocrinol Metabol. 1999;84:561–6.
15. Aoki Y, Belin RM, Clickner R, Jeffries R, Phillips L, Mahaffey KR. Serum TSH
and total T4 in the United States population and their association with
participant characteristics: National Health and Nutrition Examination Survey
(NHANES 1999–2002). Thyroid. 2007;17:1211–23.
16. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC. The
incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis.
J Clin Endocrinol Metabol. 2014;99:923–31.
17. Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media
thickness in patients with subclinical hypothyroidism: a meta-analysis.
Atherosclerosis. 2013;227:18–25.
18. Bauer DC, Ettinger B, Browner WS. Thyroid functions and serum lipids in
older women: a population-based study. Am J Med. 1998;104:546–51.
19. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC.
Subclinical hypothyroidism is an independent risk factor for atherosclerosis
and myocardial infarction in elderly women: the Rotterdam Study. Ann
Intern Med. 2000;132:270–8.
20. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al.
Clinical risk factors for age-related macular degeneration: a systematic
review and meta-analysis. BMC Ophthalmol. 2010;10:31.
21. Klein R, Cruickshanks KJ, Myers CE, Sivakumaran TA, Iyengar SK, Meuer SM,
et al. The relationship of atherosclerosis to the 10-year cumulative
incidence of age-related macular degeneration: the Beaver Dam studies.
Ophthalmology. 2013;120:1012–9.
22. Hofman A, Darwish Murad S, van Duijn CM, Franco OH, Goedegebure A,
Ikram MA, et al. The Rotterdam Study: 2014 objectives and design update.
Eur J Epidemiol. 2013;28:889–926.
23. Klein R, Davis MD, Magli YL, Segal P, Klein BE, Hubbard L. The Wisconsin
age-related maculopathy grading system. Ophthalmology. 1991;98:1128–34.
24. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An
international classification and grading system for age-related maculopathy
and age-related macular degeneration, The International ARM Epidemiological
Study Group. Surv Ophthalmol. 1995;39:367–74.
25. Klein R, Meuer SM, Myers CE, Buitendijk GH, Rochtchina E, Choudhury F,
et al. Harmonizing the classification of age-related macular degeneration in
the three-continent AMD consortium. Ophthalmic Epidemiol. 2014;21:14–23.
26. Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013
ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J.
2013;2:215–28.
27. Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, et al.
Seven new loci associated with age-related macular degeneration.
Nature Genetics. 45(4):433–439.
28. Porcu E, Medici M, Pistis G, Volpato CB, Wilson SG, Cappola AR, et al. A meta-
analysis of thyroid-related traits reveals novel loci and gender-specific differences
in the regulation of thyroid function. PLoS Genet. 2013;9, e1003266.
29. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H,
et al. Discovery of common variants associated with low TSH levels and
thyroid cancer risk. Nat Genet. 2012;44:319–22.
30. Bromfield S, Keenan J, Jolly P, McGwin Jr G. A suggested association
between hypothyroidism and age-related macular degeneration. Curr Eye
Res. 2012;37:549–52.31. Age-Related Eye Disease Study Research Group. Risk factors associated with
age-related macular degeneration. A case–control study in the age-related
eye disease study: Age-Related Eye Disease Study Report Number 3.
Ophthalmology. 2000;107:2224–32.
32. Klein R, Klein BE, Jensen SC, Cruickshanks KJ, Lee KE, Danforth LG, et al.
Medication use and the 5-year incidence of early age-related maculopathy:
the Beaver Dam Eye Study. Arch Ophthalmol. 2001;119:1354–9.
33. Douglas IJ, Cook C, Chakravarthy U, Hubbard R, Fletcher AE, Smeeth L.
A case–control study of drug risk factors for age-related macular
degeneration. Ophthalmology. 2007;114:1164–9.
34. Ng L, Lyubarsky A, Nikonov SS, Ma M, Srinivas M, Kefas B, et al. Type 3
deiodinase, a thyroid-hormone-inactivating enzyme, controls survival and
maturation of cone photoreceptors. J Neurosci. 2010;30:3347–57.
35. Nguyen-Legros J, Hicks D. Renewal of photoreceptor outer segments and
their phagocytosis by the retinal pigment epithelium. Int Rev Cytol.
2000;196:245–313.
36. Biondi B, Cooper DS. The clinical significance of subclinical thyroid
dysfunction. Endocr Rev. 2008;29:76–131.
37. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, et al.
Association between serum free thyroxine concentration and atrial
fibrillation. Arch Intern Med. 2007;167:928–34.
38. Waring AC, Arnold AM, Newman AB, Buzkova P, Hirsch C, Cappola AR.
Longitudinal changes in thyroid function in the oldest old and survival:
the cardiovascular health study all-stars study. J Clin Endocrinol Metabol.
2012;97:3944–50.
39. Meier CA, Maisey MN, Lowry A, Muller J, Smith MA. Interindividual
differences in the pituitary-thyroid axis influence the interpretation of
thyroid function tests. Clin Endocrinol (Oxf). 1993;39:101–7.
40. Fliers E, Kalsbeek A, Boelen A. Beyond the fixed setpoint of the
hypothalamus-pituitary-thyroid axis. Eur J Endocrinol. 2014;171:R197–208.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
